New drug cocktail shows promise for Hard-to-Treat blood cancers

NCT ID NCT04447027

Completed Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This early-phase trial tested a combination of four drugs (romidepsin, CC-486, dexamethasone, and lenalidomide) in 26 adults with T-cell cancers that had returned or stopped responding to prior treatments. The main goal was to find a safe dose and check for side effects. While the study is too small to prove effectiveness, it provides initial safety data and hints at possible tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: romidepsin, CC-486 (5-azacitidine), dexamethasone, and lenalidomide
What this could lead to: If this combination proves safe and effective, it could offer a new treatment option for people with T-cell cancers that have stopped responding to standard therapies.
What could go wrong: This is a very early phase 1 trial with only 26 participants, so the benefits are uncertain. The drug combination can cause severe side effects, and it is not expected to cure the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma neoplasm of mature T-cells or NK-cells primary cutaneous T-cell non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS T-CELL LYMPHOMA MATURE T-CELL MALIGNANCIES PERIPHERAL T-CELL LYMPHOMA RELAPSED/ REFRACTORY T-CELL MALIGNANCIES

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.